Further, in mouse models of pancreatic cancer, BRCA2 mutations are associated with an immune ‘desert’ phenotype, while PALB2 mutant models show intermediate infiltration by immune cells [110]. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.